Acute Care Therapeutics for Surgical Settings
Baudax Bio is a pharmaceutical company focused on developing and commercializing innovative products for acute care settings.
!— Global site tag (gtag.js) – Google Analytics —> https://www.googletagmanager.com/gtag/js?id=UA-173161930-1">
Baudax Bio Announces Positive Top-Line Final Results From Phase 2 Randomized Clinical Trial of BX1000View Press Release
Baudax Bio to Host Key Opinion Leader Webinar to Discuss Results of Phase 2 BX1000 TrialView Press Release
Baudax Bio Announces Positive Results from 2nd Interim Analysis of Phase 2 Randomized Trial for BX1000View Press Release
Baudax Bio Reports 2022 Fourth Quarter and Annual Financial Results and Provides Business UpdateView Press Release
Baudax Bio Announces Positive Outcome of Interim Analysis of Phase II Randomized Trial for BX1000View Press Release
Stay informed and receive company updates straight to your inbox.